News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hybrigenics Appoints Dr Alain Munoz to its Board of Directors



10/5/2011 10:55:57 AM

Paris, October 5, 2011 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases and specialised in protein interactions, announces today the appointment of Dr Alain Munoz to its board as a non-executive independent director. Dr Munoz replaces Dr Bernhard Ehmer, president of ImClone Systems, and will chair the clinical advisory board.

Dr Munoz, cardiologist and anaesthesiologist by training, has over 20 years’ experience in the pharmaceutical industry at senior management level with the Sanofi Group as R&D vice-president (VP) and the French pharmaceutical company Fournier as VP of R&D and business development, subsequently becoming senior VP of the pharmaceutical division. Under his leadership, numerous drug product registrations were obtained world-wide, generating significant sales (Adenocard(R), Plavix(R), Lipanthyl(R)/Tricor(TM), Esclim(R)). He has an in-depth knowledge of the US and Japanese markets, and has concluded several major licensing deals with world-class partners in the industry. He currently acts as an entrepreneur developing his own projects and an adviser to investors. He is a board member of several biotechnology companies (NYSE Euronext: Vivalis SA, VLS; Novagali Pharma SA, NOVA. Nasdaq OMX: Zealand Pharma A/S, ZEAL).

“I'm delighted to welcome Alain Munoz to the board of Hybrigenics. Alain brings scientific and clinical know how as well as competence in the management of a public French company, thereby complementing the existing competences of the company's board,” said Daan Ellens, chairman of Hybrigenics’ board of directors. “I’d like to warmly thank Bernhard Ehmer who has accompanied Hybrigenics’ clinical development from scratch in 2006 until the successful completion of Phase IIa of inecalcitol in castrate-resistant prostate cancer this year,” added Remi Delansorne, Hybrigenics’ CEO.

About Hybrigenics

Hybrigenics (http://www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.

Hybrigenics’ current development program is based on inecalcitol, a vitamin D receptor agonist, for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere(R), which is the current gold-standard chemotherapeutic treatment for this indication. Inecalcitol is also being developed to treat moderate-to-severe psoriasis by oral administration.

Hybrigenics’ research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

Hybrigenics Services SAS, a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

Mark Tidmarsh

ANDREW LLOYD & ASSOCIATES

http://www.ala.com

mark@ala.com

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND

Tel: +44 1273 675100

Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE

Tel: +33 1 56 54 07 00

Fax: +33 1 56 54 07 01


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES